anti-GPR37 antibody product blog
Tags: Antibody; Polyclonal Antibody; anti-GPR37 antibody; GPR37; PAEL Receptor;
The GPR37 gpr37 (Catalog #MBS628990) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The PAEL Receptor, CT (Probable G-protein Coupled Receptor 37, Endothelin B Receptor-like Protein-1, ETBR-LP-1, Parkin-associated Endothelin Receptor-like Receptor, PAELR, GPR37) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s PAEL Receptor can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB), Immunohistochemistry (IHC).Suitable for use in ELISA, Western Blot, and Immunohistochemistry.
Dilution: ELISA: 1:1,000
Western Blot: 1:100-1:500
Immunohistochemistry: 1:50-1:100. Researchers should empirically determine the suitability of the GPR37 gpr37 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The GPR37 gpr37 product has the following accession number(s) (GI #4885323) (NCBI Accession #NP_005293.1) (Uniprot Accession #O15354). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the PAEL Receptor, CT (Probable G-protein Coupled Receptor 37, Endothelin B Receptor-like Protein-1, ETBR-LP-1, Parkin-associated Endothelin Receptor-like Receptor, PAELR, GPR37) with the following immunoassay(s):
Western Blot (WB) (Western blot analysis of anti-Pael-R (GPR37) Antibody (C-term) in K562 cell line lysates (35ug/lane). Pael-R (arrow) was detected using the purified Pab.)
Western Blot (WB) (Western blot analysis of anti-Pael-R (GPR37) Pab in mouse brain tissue lysate. Pael-R (GPR37) (arrow) was detected using the purified Pab.)
Immunohistochemistry (IHC) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known; however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function. Panneuronal expression of Parkin substrate Pael-R causes age-dependent selective degeneration of Drosophila dopaminergic (DA) neurons; coexpression of Parkin degrades Pael-R and suppresses its toxicity.
Immunogen: Synthetic peptide in the C-terminal region of human Pael-R (GPR37) (KLH). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing GPR37 are readily searchable from our website. Different antibodies against the same target such as GPR37 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.